Compare MSAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | BIVI |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 11.1M |
| IPO Year | N/A | 2013 |
| Metric | MSAI | BIVI |
|---|---|---|
| Price | $5.88 | $1.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | 46.8K | ★ 95.4K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $98.45 | N/A |
| Revenue Next Year | $38.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.88 |
| 52 Week High | $7.20 | $9.09 |
| Indicator | MSAI | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 62.94 | 36.96 |
| Support Level | $0.37 | $1.16 |
| Resistance Level | $6.97 | $1.32 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 30.53 | 9.82 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.